Literature DB >> 2339361

Increased whole blood viscosity during coronary artery bypass surgery. Studies to evaluate the effects of soluble fibrin and poloxamer 188.

R L Hunter1, C Papadea, C J Gallagher, D C Finlayson, I J Check.   

Abstract

This study was designed to test the hypothesis that soluble fibrin complexes resulting from the trauma of surgery could produce elevated blood viscosity, to characterize the soluble fibrin polymers, and to evaluate in vitro the effect of a new hemorheologic agent, poloxamer 188, on viscosity in these abnormal situations. Ten patients undergoing aortocoronary bypass surgery were studied before and at various times after surgery. By 6 h after surgery, the mean hematocrit decreased by 23%, fibrinogen decreased 48%, and erythrocyte sedimentation rate decreased 33%, whole blood viscosity at a low shear rate rose on average of 69% and soluble fibrin rose 118%. Over the 6-day observation period, the concentrations of soluble fibrin paralleled the changes in viscosity, whereas the concentrations of fibrinogen varied nearly inversely with viscosity. The effects of various forms of fibrinogen and fibrin were tested by additions to normal blood. Soluble fibrin polymers, but not fibrin monomers, increased blood viscosity two to three fold. Poloxamer 188 reduced the viscosity of all patient samples to the normal range. These data support the hypothesis that increased whole blood viscosity at low shear rates is caused by hydrophobic adhesion of fibrin polymers to red cells and that poloxamer 188 normalizes viscosity by effectively disrupting the weak hydrophobic bonds.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2339361

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  The purified vepoloxamer prevents haemolysis in 42-day stored, DEHP/PVC-free red blood cell units.

Authors:  Jose A Cancelas; Neeta Rugg; Shawnagay Nestheide; Sarah E Hill; R Martin Emanuele; Douglas S Mckenzie
Journal:  Blood Transfus       Date:  2017-03       Impact factor: 3.443

2.  Effect of Poloxamer 188 on Collateral Blood Flow, Myocardial Infarct Size, and Left Ventricular Function in a Canine Model of Prolonged (3-Hour) Coronary Occlusion and Reperfusion.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-07       Impact factor: 2.300

3.  Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331.

Authors:  R L Hunter; C Jagannath; A Tinkley; C A Behling; F Nolte
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 4.  Sickle cell anaemia: progress in pathogenesis and treatment.

Authors:  Samir K Ballas
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Differential effects of commercial-grade and purified poloxamer 188 on renal function.

Authors:  Martin Emanuele; Balu Balasubramaniam
Journal:  Drugs R D       Date:  2014-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.